CellCept (mycophenolate mofetil)

The active substance in CellCept, mycophenolate mofetil, is an immunosuppressive medicine. In the body, it is converted into mycophenolic acid, which blocks an enzyme called ‘inosine monophosphate dehydrogenase’. This enzyme is important for the formation of DNA in cells, particularly in the lymphocytes (a type of white blood cell which is involved in the rejection of organ transplants). By preventing the production of new DNA, CellCept reduces the rate at which the lymphocytes multiply. This makes them less effective at recognising and attacking the transplanted organ, lowering the risk of the organ being rejected.¹

In Bangladesh CellCept is approved for the following indications.²

CellCept in combination with corticosteroids and either ciclosporin or tacrolimus is indicated for:

• prophylaxis of acute organ rejection and treatment of first or refractory organ rejection in patients receiving allogeneic renal transplants
• prophylaxis of acute organ rejection in patients receiving allogeneic cardiac transplants. (In the treated population, MMF improved survival in the first year after transplantation).
• prophylaxis of acute organ rejection in patients receiving allogeneic hepatic transplants

CellCept is indicated for induction and maintenance therapy of patients with Class III-V lupus nephritis (diagnosed according to International Society of Nephrology/Renal Pathology Society classification).

For more disease and medicine related queries you may discuss with your physician.

In Bangladesh CellCept is available as

Tablets 500 mg

References

1. CellCept | European Medicines Agency. [Internet; cited 2018, November 12]. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/cellcept

2. CellCept Product Information _ BD Ro 106-1443_June 2021